ClinicalTrials.gg
CompletedNCT04994743Updated Oct 11, 2021

Safety, Tolerability, and Pharmacokinetic Study of CORT113176 in Healthy Participants

A Phase 1 interventional study of CORT113176 and Placebo matching CORT113176 in Healthy Adults, sponsored by Corcept Therapeutics. Completed at 1 site in Netherlands. Open to male participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-10-11.

Sponsored by Corcept Therapeutics · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
Male
01

Study summary

This is a safety, tolerability, and pharmacokinetic study in 2 cohorts of healthy male participants with an option for an additional cohort. Cohorts 1 and 2 will receive once daily by mouth CORT113176 150 mg and 300 mg, respectively, for 14 days under fed conditions. Progression from Cohort 1 to Cohort 2 will be done based on the safety and tolerability outcome in Cohort 1 and after Cohort 1 has received the study drug for at least 7 days. The optional Cohort 3 may receive a higher dose that will not exceed CORT113176 450 mg once daily by mouth for 14 days under fed conditions. The progression from Cohort 2 to the optional cohort (Cohort 3) will be based on the same precautions as with the progression from Cohort 1 to Cohort 2. Each participant will undergo safety evaluations. Pharmacokinetics of CORT113176 will be assessed in plasma and cerebrospinal fluid (CSF) samples. Pharmacodynamic assessments will include the measurement of serum cortisol.

02

Conditions studied

  • Healthy Adults
03

In context

Lead sponsor

Corcept Therapeutics is the lead sponsor of 73 studies on the registry; 3 are open to participants now.

Of its 32 completed or terminated interventional studies of FDA-regulated products, 9 (28%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (BMI) of 18.0 to 30.0 kg/m\^2, inclusive
  • Body weight ≤100 kg.
  • Must agree to adhere to the requirements on , exposure to sexual partners, and sperm donation as defined in the protocol
  • Additional criteria apply.

Exclusion criteria

Exclusion Criteria:

  • Received any drug in a clinical research study within the last 90 days
  • History of alcohol abuse or drug addiction (including soft drugs like cannabis products) within past 5 years.
  • Regular alcohol consumption
  • Positive drug, nicotine (cotinine), or alcohol screen
  • Current smokers, user of e-cigarettes and nicotine replacement products and those who have used these products within the last 3 months
  • Have a pregnant partner
  • abnormal clinical chemistry, hematology (including coagulation), or urinalysis
  • Positive surface antigen (HBsAg), virus (HCV) antibody or (HIV) results
  • Positive nasopharyngeal polymerase chain reaction (PCR) test for severe acute respiratory syndrome Covid Virus-2 (SARS-CoV-2) on Day -1 or within 8 weeks prior to screening.
  • Contact with COVID-19 positive (or suspected) persons within 14 days prior to first dose
  • Active renal and/or hepatic disease
  • History of clinically significant cardiovascular, renal, hepatic, endocrine, metabolic, respiratory, gastrointestinal (GI), neurological, or psychiatric disorder
  • Abnormalities in brain and lumbar spine, or other medical or surgical conditions or clinically significant abnormal findings, for which lumbar puncture is
  • History of clinically significant back pain, back pathology and/or back injury
  • History of significant active bleeding or coagulation disorder or have taken non-steroidal anti-inflammatory drugs or other drugs that affect coagulation or function within 14 days prior to lumbar puncture
  • Allergy to lidocaine (Xylocaine®) or its derivatives
  • Any form of cancer within the 5 years (exceptions apply)
  • History and/or symptoms of adrenal insufficiency
  • Have a condition that could be aggravated by antagonism
  • Donation or loss of greater than 400 mL of blood within the previous 3 months
  • Currently using glucocorticoids or have a history of systemic glucocorticoid use at any dose within the last 12 months or 3 months for inhaled products
  • Additional criteria apply.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    Cohort 1: CORT113176 150 mg

    Participants will receive CORT113176 150 mg lipid capsule formulation by mouth once daily under fed conditions for 14 days.

    Drug: CORT113176

  • Placebo comparator
    Cohort 1: Placebo matching CORT113176

    Participants will receive placebo matching CORT113176 capsule by mouth once daily under fed conditions for 14 days.

    Drug: Placebo matching CORT113176

  • Experimental
    Cohort 2: CORT113176 300 mg

    Participants will receive CORT113176 300 mg lipid capsule formulation by mouth once daily under fed conditions for 14 days. Progression from Cohort 1 to 2 will be done based on safety and tolerability outcome from Cohort 1 and only after Cohort 1 has received study drug for ≥7 days.

    Drug: CORT113176

  • Placebo comparator
    Cohort 2: Placebo matching CORT113176

    Participants will receive placebo matching CORT113176 capsule by mouth once daily under fed conditions for 14 days.

    Drug: Placebo matching CORT113176

  • Experimental
    Cohort 3: CORT113176 ≥300 mg

    Participants will receive CORT113176 ≥300 mg not to exceed 450 mg lipid capsule formulation by mouth once daily under fed conditions for 14 days. Cohort 3 is optional, and progression from Cohort 2 to 3 be done based on safety and tolerability outcome from Cohort 2 and only after Cohort 2 has received study drug for ≥7 days.

    Drug: CORT113176

  • Placebo comparator
    Cohort 3: Placebo matching CORT113176

    Participants will receive placebo matching CORT113176 capsule by mouth once daily under fed conditions for 14 days.

    Drug: Placebo matching CORT113176

Interventions

  • CORT113176 lipid capsule formulation for oral administration

  • DrugPlacebo matching CORT113176

    Placebo matching CORT113176 lipid capsule formulation for oral administration

06

What researchers measure

Primary outcomes

  1. Number of Participants with One or More Adverse Events

    Time frame: Up to Day 28

Secondary outcomes

  1. Maximum Plasma Concentration (Cmax) of CORT113176

    Time frame: Before dosing and a pre-specified time points up to Day 17

  2. Time of Cmax (Tmax) of Plasma CORT113176

    Time frame: Before dosing and a pre-specified time points up to Day 17

  3. Apparent Elimination Half-life (t1/2) of Plasma CORT113176

    Time frame: Before dosing and a pre-specified time points up to Day 17

  4. Area Under the Plasma Concentration-time Curve (AUC) of Plasma CORT113176

    Time frame: Before dosing and a pre-specified time points up to Day 17

  5. Cerebrospinal Fluid Concentration of CORT113176

    Time frame: Approximately 3 and 5 hours after dosing on Day 7

  6. Serum Concentration of Cortisol

    Time frame: Before and approximately 12 hours after dosing on Days 1, 7, and 14

07

Study locations

1 site
  • Site 01
    Groningen, 9728 NZ, Netherlands
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2021 to primary completion in Sep 2021, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 29, 2021
First posted
Aug 6, 2021
StartActual
Jul 13, 2021
Primary completionActual
Sep 30, 2021
CompletionActual
Sep 30, 2021
Last update
Oct 11, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 11, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04994743
Responsible party
Sponsor
First posted
Aug 6, 2021
Start date
Jul 13, 2021
Primary completion
Sep 30, 2021
Completion
Sep 30, 2021
Last update
Oct 11, 2021

Study contacts

Hazel Hunt, Ph.D.
study director · Corcept Therapeutics

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: CORT113176

Start the discussion